PYCR2 and neoplasm: In this regard, we obtained reproducible outcomes from two different CRC cell lines, HCT116 and SW620, finding that inhibiting PYCR2 inhibits cell survival, anchorage-independent growth, and invasive mobility, as well as in vivo tumor growth.